DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dexlansoprazole

First Posted Date: 2017-10-23

Last Posted Date: 2019-05-10

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT03316976

Locations: 🇨🇳
Phase I Clinical Trial Department, Beijing, Beijing, China

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Phase 1

Completed

Conditions: Renal Impairment
Healthy Volunteers

Interventions: Drug: TAK-954

First Posted Date: 2017-09-28

Last Posted Date: 2020-08-25

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT03296787

Locations: 🇨🇿
PRA CZ, s.r.o, Praha 7, Praha, Czechia
🇨🇿
Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia
🇭🇺
PRA Magyarorszag Kft., Budapest, Hungary

and more 1 locations

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

Phase 2

Completed

Conditions: Idiopathic Gastroparesis
Diabetic Gastroparesis

Interventions: Drug: TAK-954
Drug: Placebo

First Posted Date: 2017-09-13

Last Posted Date: 2021-01-07

Lead Sponsor: Takeda

Target Recruit Count: 36

Registration Number: NCT03281577

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: TAK-954

First Posted Date: 2017-09-11

Last Posted Date: 2019-09-25

Lead Sponsor: Takeda

Target Recruit Count: 25

Registration Number: NCT03277274

Locations: 🇸🇰
Summit Center of Clinical Research, Bratislava, Slovakia
🇨🇿
PRA CZ, s.r.o, Praha 7, Praha, Czechia

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Phase 3

Completed

Conditions: Myelodysplastic Syndrome
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Azacitidine
Drug: Pevonedistat

First Posted Date: 2017-08-31

Last Posted Date: 2024-10-28

Lead Sponsor: Takeda

Target Recruit Count: 454

Registration Number: NCT03268954

Locations: 🇺🇸
Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Baptist Health System (N Kendall) - USOR, Miami, Florida, United States

and more 199 locations

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Phase 1

Completed

Conditions: Japanese Healthy Adult Male Participants

Interventions: Drug: TAK-906 Placebo
Drug: TAK-906

First Posted Date: 2017-08-02

Last Posted Date: 2021-01-12

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03237156

Locations: 🇯🇵
Sekino Clinical Pharmacology Clinic, Toshima, Tokyo, Japan

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab IV
Drug: Placebo

First Posted Date: 2017-07-31

Last Posted Date: 2023-03-01

Lead Sponsor: Takeda

Target Recruit Count: 215

Registration Number: NCT03234907

Locations: 🇨🇳
Gastroenterology, Hangzhou, Zhejiang, China

Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Trelagliptin
Drug: Alogliptin

First Posted Date: 2017-07-27

Last Posted Date: 2023-12-22

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT03231709

Locations: 🇯🇵
OCROM Clinic, Suita, Osaka, Japan
🇯🇵
ToCROM Clinic, Shinjuku, Tokyo, Japan

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-418
Drug: TAK-418 Placebo

First Posted Date: 2017-07-24

Last Posted Date: 2019-09-09

Lead Sponsor: Takeda

Target Recruit Count: 40

Registration Number: NCT03228433

Locations: 🇺🇸
PAREXEL International, Glendale, California, United States

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Phase 3

Recruiting

Conditions: Moderately to Severely Active Ulcerative Colitis

Interventions: Drug: Vedolizumab IV
Drug: Placebo

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 402

Registration Number: NCT03221036

Locations: 🇨🇳
Gastroenterology, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy